{"id":456434,"date":"2021-03-11T16:28:41","date_gmt":"2021-03-11T21:28:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456434"},"modified":"2021-03-11T16:28:41","modified_gmt":"2021-03-11T21:28:41","slug":"neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/","title":{"rendered":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MALVERN, Pa., March  11, 2021  (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company\u2019s Vice President, R&amp;D and Clinical, will retire effective March 31, 2021.<\/p>\n<p>\u201cI am grateful to Greg for his outstanding leadership of Neuronetics\u2019 product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,\u201d said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. \u201cI have a lot of faith in our team and know they will continue operating at a high level to drive R&amp;D and clinical innovation under the interim leadership of Cory Anderson, our recently appointed Vice President, Clinical Affairs and Medical Operations.\u201d<\/p>\n<p>Mr. Harper will serve as a consultant to the company through June 30, 2021 to assist with the transition of his responsibilities. \u201cSince joining Neuronetics in 2016, I have been impressed by the Company\u2019s technology and people, as well as the passion to transform neurohealth by bringing revolutionary technologies for those suffering from MDD and other psychiatric disorders,\u201d said Mr. Harper. \u201cI believe the team is positioned extremely well to succeed in the short- and longer-term on our R&amp;D and clinical priorities.\u201d<\/p>\n<p>\n        <strong>About Neuronetics<\/strong><br \/>\n        <br \/>Neuronetics, Inc.\u00a0is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar<sup>\u00ae<\/sup> Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the\u00a0United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including\u00a0Japan, where it is listed under Japan\u2019s national health insurance. Additional information can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WB4Mq32eAQ_z6EtJF-0raqpk63ZmLv_qYZuOV7lavyMiqoLsB6d17bnAkgBFf3yHpnn4OrWzNzmsNd-iwhHseJSqUQwEVA28KA_G8xSUevE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>www.neuronetics.com<\/strong><\/a>.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Chelsey Manko<br \/>Vault Communications<br \/>610-455-2778<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KG5ba5Z91TjDRWDv1A2p5a1061Cv8B7BYBKLSNtqdbP_X_Dt6_F1BeSuWrLp-Gc67ngxvg_12srtDRgKtakvpi3cQuH1Y5vC_3Cc7m76sIoh5PpjNFtySfvIvXJswAth\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cmanko@vaultcommunications.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4864a87f-abf9-4bd8-975f-9347cff19bbe\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company\u2019s Vice President, R&amp;D and Clinical, will retire effective March 31, 2021. \u201cI am grateful to Greg for his outstanding leadership of Neuronetics\u2019 product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,\u201d said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. \u201cI have a lot of faith in our team and know they will continue operating at a high level to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company\u2019s Vice President, R&amp;D and Clinical, will retire effective March 31, 2021. \u201cI am grateful to Greg for his outstanding leadership of Neuronetics\u2019 product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,\u201d said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. \u201cI have a lot of faith in our team and know they will continue operating at a high level to &hellip; Continue reading &quot;Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T21:28:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical\",\"datePublished\":\"2021-03-11T21:28:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/\"},\"wordCount\":392,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/\",\"name\":\"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\",\"datePublished\":\"2021-03-11T21:28:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk","og_description":"MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company\u2019s Vice President, R&amp;D and Clinical, will retire effective March 31, 2021. \u201cI am grateful to Greg for his outstanding leadership of Neuronetics\u2019 product development function over the past five years and more recently clinical affairs. Greg has made enormous contributions to our organization,\u201d said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. \u201cI have a lot of faith in our team and know they will continue operating at a high level to &hellip; Continue reading \"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-11T21:28:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical","datePublished":"2021-03-11T21:28:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/"},"wordCount":392,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/","name":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=","datePublished":"2021-03-11T21:28:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODgyNyM0MDYwNjgzIzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-retirement-of-gregory-harper-vice-president-rd-and-clinical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics Announces Retirement of Gregory Harper, Vice President, R&amp;D and Clinical"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}